Therapeutic monoclonal antibodies and related products have steadily grown to become the
dominant product class within the biopharmaceutical market. Production of antibodies …

Downstream processing is considered one of the most challenging phases of industrial
manufacturing of therapeutic proteins, accounting for a large portion of the total production …

In the present work, a generic non-reducing capillary electrophoresis sodium dodecyl
sulphate (nrCE-SDS) method was tested for a wide range of 26 FDA and EMA approved …

Antibody disulfide bond reduction has been a challenging issue in monoclonal antibody
manufacturing. It could lead to a decrease of product purity and failure to meet the targeted …

Monoclonal antibody interchain disulfide bond reduction was observed in a Chinese
Hamster Ovary manufacturing process that used single‐use technologies. A similar …

Free sulfhydryls are important properties of protein products including monoclonal
antibodies (mAbs). Here, a new technology, variable pathlength extension (SoloVPE), is …

Thermostable exoshells (tES) are engineered proteinaceous nanoparticles used for the
rapid encapsulation of therapeutic proteins/enzymes, whereby the nanoplatform protects the …

Background Hepatocelular carcinoma is one of the leading cancer types with no effective
cure as poor prognosis is still a challenging aspect. Thus, alternative therapeutics are …

Disulfide bonds play a crucial role in folding and structural stabilization of monoclonal
antibodies (mAbs). Disulfide bond reduction may happen during the mAb manufacturing …

Therapeutic monoclonal antibodies (mAbs), primarily immunoglobin G1 (IgG1) and IgG4
with an engineered CPPC motif in its hinge region, are predominant biologics. Inter-chain …